Parkinson's disease, insulin resistance and novel agents of neuroprotection.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Brain : a journal of neurology

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/brain/aws009PMID 22344583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Diabetes and Cancer

  2012cited by this paper
• A feedforward loop links Gaucher and Parkinson's diseases?

  2011cited by this paper
• Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.

  2011cited by this paper
• Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

  2011cited by this paper
• Exploring the link between glucocerebrosidase mutations and parkinsonism.

  2011cited by this paper
• Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2

  2011cited by this paper
• Running reduces stress and enhances cell genesis in aged mice.

  2011cited by this paper
• Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

  2011influential reference
• Obesity, diabetes, and risk of Parkinson's disease

  2011cited by this paper
• Mitophagy: the latest problem for Parkinson's disease.

  2011cited by this paper
• Broad activation of the ubiquitin–proteasome system by Parkin is critical for mitophagy

  2011cited by this paper
• Oxidized DJ-1 Interacts with the Mitochondrial Protein BCL-XL*

  2011cited by this paper
• PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease.

  2011cited by this paper
• Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.

  2011cited by this paper
• Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?

  2011cited by this paper
• Mineralocorticoid receptor activation restores medial perforant path LTP in diabetic rats

  2010cited by this paper
• Autophagy gone awry in neurodegenerative diseases

  2010cited by this paper
• Diabetes and Cancer: A Consensus Report

  2010cited by this paper
• Faculty Opinions recommendation of Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes.

  2010cited by this paper
• Complex I: inhibitors, inhibition and neurodegeneration.

  2010cited by this paper
• Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo.

  2010cited by this paper
• Alzheimer disease.

  2010cited by this paper
• PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease

  2010cited by this paper
• Cognitive impairment following high fat diet consumption is associated with brain inflammation.

  2010cited by this paper
• Exendin‐4 protects pancreatic beta cells from human islet amyloid polypeptide‐induced cell damage: potential involvement of AKT and mitochondria biogenesis

  2010cited by this paper
• Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients.

  2010cited by this paper
• Diabetes and Cancer

  2010cited by this paper
• Aging-Related Gene Expression in Hippocampus Proper Compared with Dentate Gyrus Is Selectively Associated with Metabolic Syndrome Variables in Rhesus Monkeys

  2010cited by this paper
• Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics.

  2010cited by this paper
• Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells

  2010cited by this paper
• Neural mechanisms of ageing and cognitive decline

  2010cited by this paper
• Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes

  2010cited by this paper
• Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.

  2009influential reference
• Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density.

  2009cited by this paper
• Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression.

  2009cited by this paper
• Ciliary neurotrophic factor recruitment of glucagon‐like peptide‐1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons

  2009cited by this paper
• GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

  2009cited by this paper
• Single Nigrostriatal Dopaminergic Neurons Form Widely Spread and Highly Dense Axonal Arborizations in the Neostriatum

  2009cited by this paper
• Type II Diabetes in Mild Cognitive Impairment and Alzheimer's Disease: Results from a Prospective Population-Based Study in Germany

  2009cited by this paper
• PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia.

  2009cited by this paper
• Peroxidase Mechanism of Lipid-dependent Cross-linking of Synuclein with Cytochrome c

  2009cited by this paper
• The Relationship between Dopaminergic Axons and Glutamatergic Synapses in the Striatum: Structural Considerations

  2009cited by this paper
• Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

  2009cited by this paper
• Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain*

  2008cited by this paper
• Proteomics Analysis Identifies Phosphorylation-dependent α-Synuclein Protein Interactions *S

  2008cited by this paper
• N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking

  2008cited by this paper
• The insulin paradox: aging, proteotoxicity and neurodegeneration

  2008cited by this paper
• The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B

  2008cited by this paper
• Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

  2008influential reference
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons

  2008cited by this paper
• Noncompaction and endocarditis in suspected mitochondrial disorder.

  2008cited by this paper
• Mitochondria in neuroplasticity and neurological disorders.

  2008cited by this paper
• Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy?

  2008cited by this paper
• Mitochondria in the aetiology and pathogenesis of Parkinson's disease.

  2008cited by this paper
• Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

  2008cited by this paper
• Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins

  2008cited by this paper
• The role of exercise and PGC1α in inflammation and chronic disease

  2008cited by this paper
• The brain in the age of old: The hippocampal formation is targeted differentially by diseases of late life

  2008cited by this paper
• Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease

  2007cited by this paper
• Mitochondrial function and endocrine diseases

  2007cited by this paper
• Markers of mitochondrial biogenesis and metabolism are lower in overweight and obese insulin-resistant subjects.

  2007cited by this paper
• Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system

  2007cited by this paper
• Inflammation as a causative factor in the aetiology of Parkinson's disease

  2007influential reference
• PGC-1alpha Thr394Thr and Gly482Ser variants are significantly associated with T2DM in two North Indian populations: a replicate case-control study.

  2007cited by this paper
• Insulin-mediated effects of glucose on dopamine metabolism

  2007cited by this paper
• ESCI Award 2006. Mitochondrial function and endocrine diseases.

  2007cited by this paper
• Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease

  2007cited by this paper
• The Thiazolidinedione Pioglitazone Alters Mitochondrial Function in Human Neuron-Like Cells

  2007cited by this paper
• PGC-1α Thr394Thr and Gly482Ser variants are significantly associated with T2DM in two North Indian populations: a replicate case-control study

  2007cited by this paper
• Relation of diabetes to mild cognitive impairment.

  2007cited by this paper
• The Outer Mitochondrial Membrane Protein mitoNEET Contains a Novel Redox-active 2Fe-2S Cluster*

  2007cited by this paper
• MitoNEET is a uniquely folded 2Fe–2S outer mitochondrial membrane protein stabilized by pioglitazone

  2007cited by this paper
• Inflammation and metabolic disorders

  2006cited by this paper
• Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.

  2006cited by this paper
• High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease

  2006cited by this paper
• Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled

  2006cited by this paper
• Transcriptional Repression of PGC-1a by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration

  2006cited by this paper
• Body mass index and the risk of Parkinson disease

  2006influential reference
• PGC-1 coactivators: inducible regulators of energy metabolism in health and disease.

  2006cited by this paper
• The effect of diabetes and stroke at baseline and during follow-up on stroke mortality

  2006cited by this paper
• In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease.

  2006cited by this paper
• Transcriptional regulation by insulin: from the receptor to the gene.

  2006cited by this paper
• Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons

  2006cited by this paper
• Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress.

  2005cited by this paper
• A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome.

  2005cited by this paper
• Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.

  2005cited by this paper
• Diabetic neuropathies: a statement by the American Diabetes Association.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Metabolic control through the PGC-1 family of transcription coactivators.

  2005cited by this paper
• Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage.

  2005cited by this paper
• Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications

  2005cited by this paper
• PPARGC1A mRNA levels of in vitro differentiated human skeletal muscle cells are negatively associated with the plasma oleate concentrations of the donors

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD

  2005cited by this paper
• Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis.

  2005cited by this paper
• Neurodegenerative disorders associated with diabetes mellitus

  2004cited by this paper
• Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations

  2004cited by this paper
• A new Alzheimer's disease interventive strategy: GLP-1.

  2004cited by this paper

• Insulin Resistance as a Shared Pathophysiological Driver in Neurological Disorders: a Narrative Review

  2026cites this paper
• A split biotin ligase approach reveals proteins associated with oligomeric alpha-synuclein during aggregation

  2026cites this paper
• Targeting metabolic dysfunction in amyotrophic lateral sclerosis: therapeutic potential of GLP-1 receptor agonists.

  2026cites this paper
• A Split Biotin Ligase Approach to Revealing Proteins Associated with Oligomeric Alpha-Synuclein During Aggregation

  2025cites this paper
• Evaluating the Molecular Interactions between Type 2 Diabetes Mellitus and Parkinson's Disease: Role of Antidiabetic Drugs as Promising Therapeutics.

  2025cites this paper
• Associations Between Diabetes Mellitus and Neurodegenerative Diseases

  2025cites this paper
• Pirfenidone alone or combined with either dulaglutide or empagliflozin protects against fructose-induced Parkinsonian features in rats.

  2025cites this paper
• M14 substitutions in exanatide modulate alpha‐synuclein aggregation

  2025cites this paper
• The potential neuroprotective effect of empagliflozin against depressive-like behavior induced by chronic unpredictable mild stress in rats: Involvement of NLRP3 inflammasome.

  2025cites this paper
• Targeting Metabolic Dysfunction in Parkinson’s Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection

  2025cites this paper
• The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis

  2025cites this paper
• Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment

  2025cites this paper
• Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.

  2024cites this paper
• Therapeutic potentials of glucose-dependent insulinotropic polypeptide (GIP) in T2DM: Past, present, and future.

  2024cites this paper
• Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson’s disease

  2024cites this paper
• Cardiovascular dysautonomia and cognitive impairment in Parkinson's disease (Review)

  2024cites this paper
• Research progress on intranasal treatment for Parkinson's disease

  2024cites this paper
• Physiopathological Roles of White Adiposity and Gut Functions in Neuroinflammation

  2024cites this paper
• Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease

  2024cites this paper
• Metformin use is associated with reduced mortality risk in diabetic patients with Parkinson's disease.

  2024cites this paper
• Irisin in degenerative musculoskeletal diseases: functions in system and potential in therapy.

  2024cites this paper
• Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease

  2024cites this paper
• Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study.

  2024cites this paper
• Metabolic Dysfunction in Parkinson’s Disease: Unraveling the Glucose–Lipid Connection

  2024cites this paper
• Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides.

  2024cites this paper
• A research update on Exendin-4 as a novel molecule against Parkinson's disease.

  2023cites this paper
• PP1γ regulates neuronal insulin signaling and aggravates insulin resistance leading to AD-like phenotypes

  2023cites this paper
• Parkinson’s Disease and Type 2 Diabetes Mellitus: Interrelated Pathogenetic Mechanisms and Common Therapeutic Approaches

  2023cites this paper
• Melatonin as a Chronobiotic/Cytoprotective Agent in REM Sleep Behavior Disorder

  2023cites this paper
• Pathological Correlates of Cognitive Decline in Parkinson’s Disease: From Molecules to Neural Networks

  2023cites this paper
• Type 2 Diabetes (T2DM) and Parkinson’s Disease (PD): a Mechanistic Approach

  2023cites this paper
• The retina-brain axis and diabetic retinopathy

  2023cites this paper
• Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes

  2023cites this paper
• Diabetes mellitus, prediabetes and the risk of Parkinson’s disease: a systematic review and meta-analysis of 15 cohort studies with 29.9 million participants and 86,345 cases

  2023cites this paper
• Gut–Brain Axis: Role of Gut Microbiota in Neurodegenerative Disease

  2022cites this paper
• Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease

  2022cites this paper
• If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism

  2022cites this paper
• Neuroprotective and anti-inflammatory effects of pioglitazone on Parkinson's disease: A comprehensive narrative review of clinical and experimental findings.

  2022cites this paper
• Type 2 Diabetes Mellitus-associated Cognitive Dysfunction: Advances in Potential Mechanisms and Therapies.

  2022cites this paper
• Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts

  2022cites this paper
• Onset and mortality of Parkinson’s disease in relation to type II diabetes

  2022cites this paper
• [Parkinson's disease and type 2 diabetes mellitus: interrelation of pathogenetic mechanisms and general therapeutic approaches].

  2022cites this paper
• Is there a role of insulin degrading enzyme in Parkinson’s disease?

  2022cites this paper
• Gut-oriented disease modifying therapy for Parkinson's disease.

  2022cites this paper
• Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinson’s disease when considering the coexisting effects of diabetes mellitus

  2022cites this paper
• Incretin-based drugs as potential therapy for neurodegenerative diseases: Current status and perspectives.

  2022cites this paper
• Deciphering Intertwined Molecular Pathways Underlying Metabolic Syndrome Leading to Parkinson's Disease.

  2022cites this paper
• Crosstalk between neurological, cardiovascular, and lifestyle disorders: insulin and lipoproteins in the lead role

  2022cites this paper
• Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation.

  2022cites this paper
• If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism

  2022cites this paper
• Neuroprotection by resveratrol: A review on brain delivery strategies for Alzheimer’s and Parkinson’s disease

  2022cites this paper
• Association between Parkinson’s Disease and Diabetes Mellitus: From Epidemiology, Pathophysiology and Prevention to Treatment

  2022cites this paper
• Recent research progress on metabolic syndrome and risk of Parkinson’s disease

  2022cites this paper
• Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research

  2022cites this paper
• What Do Randomized Controlled Trials Inform Us About Potential Disease-Modifying Strategies for Parkinson’s Disease?

  2022cites this paper
• Irisin, An Exercise-induced Bioactive Peptide Beneficial for Health Promotion During Aging Process.

  2022cites this paper
• Thiazolidinedione use and risk of Parkinson’s disease in patients with type 2 diabetes mellitus

  2022cites this paper
• Neuroinflammation in Parkinson’s Disease – Putative Pathomechanisms and Targets for Disease-Modification

  2022cites this paper
• Neuroprotective approaches to halt Parkinson's disease progression.

  2022cites this paper
• Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model

  2022cites this paper
• Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease.

  2022cites this paper
• Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review

  2022cites this paper
• Metabolic Mechanisms Connecting Alzheimer’s and Parkinson’s Diseases: Potential Avenues for Novel Therapeutic Approaches

  2022cites this paper
• Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors

  2021cites this paper
• Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson’s Disease

  2021cites this paper
• Diabetes Mellitus is Associated with a Higher Relative Risk for Parkinson’s Disease in Women than in Men

  2021cites this paper
• Impact of the apolipoprotein E ε4 allele on early Parkinson's disease progression.

  2021cites this paper
• Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy

  2021cites this paper
• Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

  2021cites this paper
• Diabetes, insulin and new therapeutic strategies for Parkinson's disease: focus on glucagon-like peptide-1 receptor agonists.

  2021cites this paper
• Preventing and Treating of Parkinson’s Disease with a Plant-Based Diet

  2021cites this paper
• Disruption of Endoplasmic Reticulum Proteostasis in Age-Related Nervous System Disorders.

  2021cites this paper
• Fyn kinase regulates dopaminergic neuronal apoptosis in animal and cell models of high glucose (HG) treatment

  2021cites this paper
• CDK5 inhibition improves glucose uptake in insulin‐resistant neuronal cells via ERK1/2 pathway

  2021cites this paper
• Oligomeric procyanidins inhibit insulin fibrillation by forming unstructured and off-pathway aggregates

  2021cites this paper
• Systematic analysis of the molecular mechanisms mediated by coffee in Parkinson’s disease based on network pharmacology approach

  2021cites this paper
• Asociación entre comorbilidades cardiometabólicas y enfermedad de Parkinson en población mexicana

  2021cites this paper
• Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

  2021cites this paper
• Long-Term Hyperglycemia Induces α-Synuclein Aggregation and Dopaminergic Neuronal Loss in Parkinson's Disease Mouse Model

  2021cites this paper
• Expression levels of specific microRNAs are increased after exercise and are associated with cognitive improvement in Parkinson's disease

  2021cites this paper
• Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress

  2021cites this paper
• Lipocalin 2 as a link between ageing, risk factor conditions and age-related brain diseases.

  2021cites this paper
• Downregulation of long noncoding RNA SNHG7 protects against inflammation and apoptosis in Parkinson's disease model by targeting the miR‐425‐5p/TRAF5/NF‐κB axis

  2021cites this paper
• Association of Dynamic Changes in Metabolic Syndrome Status with the Risk of Parkinson’s Disease: A Nationwide Cohort Study

  2021cites this paper
• The GLP‐1/GIP dual‐receptor agonist DA5‐CH inhibits the NF‐κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP‐1 single‐receptor agonist NLY01

  2021influential citation
• Oral semaglutide in the management of type 2 DM: Clinical status and comparative analysis.

  2021cites this paper
• Downregulation of long non-coding RNA SNHG7 protects against inflammation and apoptosis in Parkinson's disease model by targeting miR-425-5p/TRAF5/NF-κB axis

  2020cites this paper
• Brain insulin resistance: role in neurodegenerative disease and potential for targeting

  2020cites this paper
• Parkinson’s Disease: Possible Mechanisms for Nutritional Approaches

  2020influential citation
• Research on developing drugs for Parkinson's disease.

  2020cites this paper
• DEMONSTRATION OF PRECISE RELATIONSHIPS AND LINKS BETWEEN TYPE 2 DIABETES MELLITUS, INSULIN RESISTANCE AND PARKINSON’S DISEASE

  2020cites this paper
• The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease

  2020cites this paper
• Apolipoprotein E ε4 genotype and risk of freezing of gait in Parkinson's disease.

  2020cites this paper
• Glycation of glyceraldehyde-3-phosphate dehydrogenase inhibits the binding with α-synuclein and RNA.

  2020cites this paper
• [Neuroendocrine and metabolic impairments in patients with Parkinson's disease].

  2020cites this paper
• Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson's Disease.

  2020cites this paper
• Peripheral insulin and amylin levels in Parkinson's disease.

  2020cites this paper
• Cynomolgus Monkeys With Spontaneous Type-2-Diabetes-Mellitus-Like Pathology Develop Alpha-Synuclein Alterations Reminiscent of Prodromal Parkinson’s Disease and Related Diseases

  2020cites this paper
• Impact of Overweight and Obesity on Functional and Clinical Outcomes of Early Parkinson's Disease.

  2020cites this paper
• Cerebrospinal fluid proteomics implicates the granin family in Parkinson’s disease

  2020cites this paper